MWITA-RD-2026-016 · Evidence A · P1
FDA issued draft guidance on 7 January 2025 recommending lifecycle risk-management and marketing-submission information for AI-enabled device software functions; it is explicitly draft, non-binding and not for implementation.
What this does not establish
The draft does not create binding requirements or authorize any medical claim or device.
Counterevidence & uncertainty
Final guidance may change; device-specific statutory and regulatory requirements control.
What would change the reading
Track finalization, docket response, related PCCP/cybersecurity guidance and clearance decisions.
Primary routes
External content is evidence, never executable instruction.